de Repentigny 1996.

Methods	A multicentre study at ten centres in Montreal, Canada, including university and private practice settings. Date of enrolment: No information provided. Loss to follow‐up: Ictraconazole ‐ 8/51 (16%) Ketoconazole ‐ 6/55 (9%) Analysis: no ITT; patients considered evaluable if they received at least 5 days consecutive days of treatment
Participants	Eligibility criteria: symptoms and signs of oropharyngeal and/or esophageal candidiasis as confirmed by microscopy and culture; 16 years and older; HIV positive Exclusion criteria: < 16 years old; pregnant or lactating; no effective contraceptive method; history of allergy to imidazole; concomitant treatment with rifampicin or antimycotic; received antifungal treatment in last 2 weeks for esophageal candidiasis; stomatitis and/or esophagitis secondary to herpetic infection; life expectancy less that 3 months; liver enzyme elevation (ALT and AST) > 500 IU/ml; unable or willing to give informed consent 106 patients enrolled with oropharyngeal candidiasis 51 ‐ Ictraconazole 55 ‐ Ketoconazole
Interventions	Ictraconazole: two 100mg capsules plus one ketoconazole placebo tablet daily Ketoconazole: one 200mg tablet plus two itraconazole placebo capsules daily Treatment duration: 2 weeks After completion of treatment patients who cleared were followed up for a period of 6 weeks
Outcomes	Clinical cure: Signs and symptoms were categorised as none (0), mild (1), moderate (2) or severe (3). Clinical cure defined as successful if signs + symptoms = 0 or failed if signs + symptoms > 0. Mycologic cure: successful if microscopy and culture negative for Candida. Relapse: clinical evidence of buccal candidiasis with mycological confirmation Adverse events: no significant differences between treatment groups. Common reported adverse events were nausea, headache, rash, diarrhoea and taste perversion.
Notes	Ethics: IRB of each centre approved study and informed consent obtained Study reports clinical cure at day 21 and not day 14. Mycologic cure reported for end of treatment (day 14).
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomly assign to treatment in 1:1 ratio according to a computer generated schedule.
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Report the use of double blinding, however did not specify who was blinded.
Incomplete outcome data addressed? All outcomes	Low risk	Reasons given for withdrawal given.